|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 36.01 USD | +0.67% |
|
-0.72% | -19.66% |
| 10-01 | Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says | MT |
| 10-01 | Xenon Pharmaceuticals Insider Bought Shares Worth $1,121,400, According to a Recent SEC Filing | MT |
| Market Cap | 3.49B 3.13B 2.89B 2.62B 4.9B 331B 4.96B 34.65B 13.76B 174B 13.09B 12.81B 551B | P/E 2026 * |
-7.76x | P/E 2027 * | -7.71x |
|---|---|---|---|---|---|
| Enterprise Value | 2.44B 2.19B 2.02B 1.83B 3.43B 232B 3.47B 24.25B 9.63B 122B 9.16B 8.97B 385B | EV / Sales 2026 * |
1,942x | EV / Sales 2027 * | 100x |
| Free-Float |
99.67% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| XENE | Delayed | |
CBOE
| XENE | Real-time | |
|
Tradegate
| XP0 | Real-time | |
|
Boerse Muenchen
| XP0 | Real-time | |
|
Deutsche Boerse AG
| XP0 | Delayed | |
|
Börse Stuttgart
| XP0 | Delayed |
Last Transcript: Xenon Pharmaceuticals Inc.
| 1 day | +0.67% | ||
| 1 week | -0.72% | ||
| Current month | -3.17% | ||
| 1 month | -2.52% | ||
| 3 months | -45.26% | ||
| 6 months | -33.63% | ||
| Current year | -19.66% |
| 1 week | 35.09 |  | 36.9 |
| 1 month | 33.38 | | 39.92 |
| Current year | 33.38 | | 72.66 |
| 1 year | 33.38 | | 72.66 |
| 3 years | 26.74 | | 72.66 |
| 5 years | 23.26 | | 72.66 |
| 10 years | 2.1 | | 72.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 50 | 2021-06-02 |
Tucker Kelly
DFI | Director of Finance/CFO | 55 | 2025-10-14 |
Matthew Ronsheim
COO | Chief Operating Officer | 54 | 2024-08-11 |
| Director | Title | Age | Since |
|---|---|---|---|
Gary Patou
BRD | Director/Board Member | 67 | 2003-12-31 |
Ian Mortimer
BRD | Director/Board Member | 50 | 2021-06-02 |
Steven Gannon
BRD | Director/Board Member | 64 | 2015-05-20 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/15/26 | Exercice | Chief Financial Officer | 15,000 | 0.0155% | ||
| 9/30/26 | Buy | Chief Executive Officer | 30,000 | 0.0310% | ||
| 9/30/26 | Buy | Chief Financial Officer | 15,000 | 0.0155% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.67% | -0.72% | -14.04% | +16.65% | 3.49B | |
| -3.10% | -4.19% | +32.67% | +59.47% | 63.48B | |
| +0.61% | +0.13% | +10.56% | +80.06% | 54.55B | |
| -1.37% | +0.45% | +9.86% | +101.09% | 53.59B | |
| -0.75% | +1.38% | +24.89% | +50.91% | 44.75B | |
| -1.30% | -4.80% | +16.05% | +114.76% | 41.62B | |
| +1.26% | -5.26% | +221.12% | +900.64% | 39.91B | |
| -0.74% | -4.46% | +11.00% | +44.65% | 32.47B | |
| +0.07% | +14.66% | +60.86% | +50.88% | 26.7B | |
| +3.72% | -6.23% | +26.01% | -8.28% | 23.36B | |
| Average | -0.09% | -1.15% | +39.90% | +141.08% | 38.39B | |
| Weighted average by Cap. | -0.54% | -1.27% | +42.53% | +154.29% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.26M 1.13M 1.04M 945K 1.77M 119M 1.79M 12.49M 4.96M 62.59M 4.72M 4.62M 198M | 26.97M 24.21M 22.35M 20.27M 37.89M 2.56B 38.35M 268M 106M 1.34B 101M 99.09M 4.26B |
| Net income | -447M -401M -371M -336M -628M -42.47B -636M -4.44B -1.76B -22.26B -1.68B -1.64B -70.6B | -486M -436M -402M -365M -682M -46.13B -691M -4.83B -1.92B -24.18B -1.82B -1.78B -76.68B |
| Net Debt | -1.05B -939M -867M -786M -1.47B -99.39B -1.49B -10.4B -4.13B -52.09B -3.93B -3.84B -165B | -789M -708M -654M -593M -1.11B -74.92B -1.12B -7.84B -3.11B -39.27B -2.96B -2.9B -125B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-27 | US$36.01 | +0.67% | 1,089,964 |
| 26-10-26 | US$35.77 | +1.22% | 726,713 |
| 26-10-23 | US$35.34 | -3.18% | 636,595 |
| 26-10-22 | US$36.50 | +1.53% | 1,375,539 |
| 26-10-21 | US$35.95 | -0.88% | 1,081,001 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- XENE Stock
Select your edition
All financial news and data tailored to specific country editions
